Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-77c89778f8-gvh9x Total loading time: 0 Render date: 2024-07-17T16:32:37.366Z Has data issue: false hasContentIssue false

1 - Ovarian Cancer Following Use of Clomiphene and Gonadotropin in Assisted Reproduction

Published online by Cambridge University Press:  31 March 2017

By
Amin Philip Makar
Edited by
Botros Rizk  and
Jan Gerris
Botros Rizk
Affiliation:
University of South Alabama
Jan Gerris
Affiliation:
Universiteit Gent, Belgium
Get access
Type
Chapter
Information
Complications and Outcomes of Assisted Reproduction , pp. 1 - 14
Publisher: Cambridge University Press
Print publication year: 2017

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Tomao, F, Lo Russo, G, Spinelli, G P, et al. Fertility drugs, reproductive strategies and ovarian cancer risk. J Ovarian Res 2014;7:51–59.CrossRefGoogle ScholarPubMed
Kurta, M L, Moysich, K B, Weissfeld, J L, et al. Use of fertility drugs and risk of ovarian cancer: results from a U.S.-based case–control study. Cancer Epidemiol Biomarkers Prev 2012;21(8):1282–92.CrossRefGoogle ScholarPubMed
Chandra, A, Martinez, G M, Mosher, W D, Abma, J C, Jones, J. Fertility, family planning, and reproductive health of U.S. women: data from the 2002 National Survey of Family Growth. Vital Health State 2005;23:1–160.Google Scholar
Stephen, E H, Chandra, A. Updated projections of infertility in the United States: 1995–2025. Fertil Steril 1998;70:30–34.CrossRefGoogle ScholarPubMed
Whittemore, A S, Harris, R, Itnyre, J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case–control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992;136:1184–203.CrossRefGoogle ScholarPubMed
Rossing, M A, Daling, J R, Weiss, N S, Moore, D E, Self, S G. Ovarian tumors in a cohort of infertile women. N Engl J Med 1994;331:771–76.CrossRefGoogle Scholar
Modan, B, Ron, E, Lerner-Geva, L, Blumstein, T, et al. Cancer incidence in a cohort of infertile women. Am J Epidemiol 1998;147:1038–42.CrossRefGoogle Scholar
Brinton, L A, Lamb, E J, Moghissi, K S, et al. Ovarian cancer risk after the use of ovulation-stimulating drugs. Obstet Gynecol 2004;103:1194–203.CrossRefGoogle ScholarPubMed
Jensen, A, Sharif, H, Frederiksen, K, Kjaer, SK. Use of fertility drugs and risk of ovarian cancer: Danish Population Based Cohort Study. BMJ 2009;338:b249.CrossRefGoogle ScholarPubMed
Mosgaard, B J, Lidegaard, O, Kjaer, S K, Schou, G, Andersen, A N. Infertility, fertility drugs, and invasive ovarian cancer: a case-control study. Fertil Steril 1997;67:1005–12.CrossRefGoogle ScholarPubMed
Rossing, M A, Tang, M T, Flagg, E W, Weiss, L K, Wicklund, K G. A case control study of ovarian cancer in relation to infertility and the use of ovulation-inducing drugs. Am J Epidemiol 2004;160:1070–78.CrossRefGoogle ScholarPubMed
Doyle, P, Maconochie, N, Beral, V, Swerdlow, A J, Tan, S L. Cancer incidence following treatment for infertility at a clinic in the UK. Hum Reprod 2002;17:2209–13.CrossRefGoogle Scholar
Franceschini, S, La Vecchia, C, Negri, E, et al. Fertility drugs and risk of epithelial ovarian cancer in Italy. Hum Reprod 1994;9:1673–75.Google Scholar
Venn, A, Watson, L, Bruinsma, F, Giles, G, Healy, D. Risk of cancer after use of infertility drugs with in-vitro fertilisation. Lancet 1999;354:1586–90.CrossRefGoogle ScholarPubMed
Shushan, A, Paltiel, O, Iscovich, J, et al. Human menopausal gonadotropin and the risk of epithelial ovarian cancer. Fertil Steril 1996;65:13–18.CrossRefGoogle ScholarPubMed
Ness, R B, Cramer, D W, Goodman, M T, et al. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case–control studies. Am J Epidemiol 2002;155:217–24.CrossRefGoogle ScholarPubMed
Harris, R, Whittemore, A S, Itnyre, J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992;136:1204–11.CrossRefGoogle ScholarPubMed
Mosgaard, B J, Lidegaard, O, Kjaer, S K, Schou, G, Andersen, A N. Ovarian stimulation and borderline ovarian tumors: a case-control study. Fertil Steril 1998;70:1049–55.CrossRefGoogle ScholarPubMed
Sanner, K, Conner, P, Bergfeldt, K, et al. Ovarian epithelial neoplasia after hormonal infertility treatment: long-term follow-up of a historical cohort in Sweden. Fertil Steril 2009;91:1152–58.CrossRefGoogle ScholarPubMed
Schüler, S, Ponnath, M, Engel, J, Ortmann, O. Ovarian epithelial tumors and reproductive factors: a systematic review. Arch Gynecol Obstet 2013; 287:1187–204.CrossRefGoogle ScholarPubMed
Rizzuto, I, Behrens, R F, Smith, L A. Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility (Review). The Cochrane Collaboration 2013;1–74.Google Scholar
Brinton, L A, Westhoff, C L, Scoccia, B, et al. Causes of infertility as predictors of subsequent cancer risk. Epidemiology 2005;16:500–07.CrossRefGoogle ScholarPubMed
Makar, A P. Prognostic studies in cancer of the ovary and fallopian tube with emphasis on the CA125 antigen and c-erbB2 oncogen. Doctoral thesis, University of Oslo, Oslo, 1993.Google Scholar
Chen, L M, Berek, J S. Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: epidemiology and risk factors. Up to date 2015;1–24. Available at www.uptoedate.comGoogle Scholar
Kurman, R J, Shih, L N. The origin and pathogenesis of epithelial ovarian cancer – a proposed unifying theory. Am J Surg Pathol 2010;34:433–43.CrossRefGoogle ScholarPubMed
Kaern, J, Trope, C G, Kristensen, G B, Abeler, V M, Pettersen, E O. DNA ploidy: the most important prognostic factor in patients with BOT of the ovary. Int J Cancer 1993;6:349–58.Google Scholar
Tropé, C G, Kristensen, G, Makar, A P. Surgery for borderline tumor of the ovary. Seminars in Surgical Oncology 2000;19:69–75.3.0.CO;2-E>CrossRefGoogle ScholarPubMed
Burger, C W, Prinssen, H M, Baak, J P A, Wagenaar, N, Kennemans, P. The management of borderline epithelial tumors of the ovary. Int J Gynecol Cancer 2000;10:181–97.CrossRefGoogle ScholarPubMed
Vaconcelos, I, de Sousa Medes, M. Conservative surgery in ovarian borderline tumours: a meta-analysis with emphasis on recurrence risk. Eur J Cancer 2015;51:620–31.Google Scholar
Sallam, H N, Abdel-Bak, M, Sallam, N H. Does ovulation induction increase the risk of gynecological cancer? FVV in ObGyn 2013;5(4):265–73.Google ScholarPubMed
Mosgaard, B J, Lidegaard, O, Kjaer, S K, et al. Infertility, fertility drugs, and invasive ovarian cancer: a case-control study. Fertil Steril 1997;67:1005–12.CrossRefGoogle ScholarPubMed
Yilmaz, S, Üna, F, Yilmaz, F, Yüzbas, D, Ilhan, S E. Evaluation of the genotoxicity of clomiphene citrate. Mutation Res 2014;759:21–27.CrossRefGoogle ScholarPubMed
Attia, A. EBM in action: does ovulation induction increase the risk of ovarian cancer? Middle East Fertil Soc J 2006;11:135–39.Google Scholar
Jäger, W, Diedrich, K, Wildt, L. Elevated levels of CA125 in serum of patients suffering from ovarian stimulation syndrome. Fertil Steril 1987;48(4):675–78.CrossRefGoogle Scholar
Hatzipetros, J, Gocze, P M, Cziraky, K, et al. Assessment of cells in the ascitic fluid of women with ovarian hyperstimulation syndrome: the clinical implications for subsequent ovarian malignancy Reprod Biol Endocrinol 2013;11:91–95.CrossRefGoogle ScholarPubMed
Makar, A. Hormone therapy in epithelial ovarian cancer. Endocrine Related Cancer 2000;7:85–93.CrossRefGoogle ScholarPubMed
Beral, V, Doll, R, Hermon, C, Peto, R, Reeves, G. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008;371(9609):303–14.Google Scholar
Lurie, G, Thompson, P, McDuffie, K E, et al. Association of estrogen and progestin potency of oral contraceptives with ovarian carcinoma risk. Obstet Gynecol 2007;109:597–607.CrossRefGoogle ScholarPubMed
Moorman, P G, Havrilesky, L J, Gierisch, J M, et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol 2013;31(33):4188–98.CrossRefGoogle ScholarPubMed
Liat, L G, Jaron, R, Liraz, O, et al. Are infertility treatments a potential risk factor for cancer development? Perspective of 30 years of follow-up. Gynecol Endocrinol 2012;28:809–14.CrossRefGoogle Scholar
Stewart, L M, Holman, C D, Aboagye-Sarfo, P, et al. In vitro fertilization, endometriosis, nulliparity and ovarian cancer risk. Gynecol Oncol 2013;128:260–64.CrossRefGoogle ScholarPubMed
Mink, P J, Sherman, M E, Devesa, S S. Incidence patterns of invasive and borderline ovarian tumors among white women and black women in the United States. Results from the SEER Program, 1978–1998. Cancer 2002;95:2380–89.CrossRefGoogle ScholarPubMed
Whittemore, A S, Harris, R, Itnyre, J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992;136:1212–20.CrossRefGoogle ScholarPubMed
Pearce, C L, Templeman, C, Rossing, M A, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 2012; 13:385–94.CrossRefGoogle ScholarPubMed
Anderson, G L, Judd, H L, Kaunitz, A M, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women’s Health Initiative randomized trial. JAMA 2003;290:739–48.CrossRefGoogle ScholarPubMed
Collaborative Group On Epidemiological Studies Of Ovarian Cancer. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 2015. Available at http://dx.doi.org/10.1016/S0140-736(14)61687Google Scholar
Lerner-Geva, L, Toren, A, Chetrit, A, et al. The risk for cancer among children of women who underwent in vitro fertilization. Cancer 2000;88:2845–47.3.0.CO;2-E>CrossRefGoogle ScholarPubMed
Kashyap, S, Moher, D, Fung, M F, Rosenwaks, Z. Assisted reproductive technology and the incidence of ovarian cancer: a meta analysis. Obstet Gynecol 2004;103:785–94.CrossRefGoogle ScholarPubMed
Li, L L, Zhou, J, Qian, X J, Chen, Y D. Meta-analysis on the possible association between in vitro fertilization and cancer risk. Int J Gynecol Cancer 2013;23:16–24.CrossRefGoogle ScholarPubMed
Siristatidis, C, Sergentanis, T N, Kanavidis, P, et al. Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer. A systematic review and meta-analysis. Hum Reprod Update 2013;19(2):105–23.CrossRefGoogle ScholarPubMed
Venn, A, Wartson, L, Lumley, J, et al. Breast and ovarian cancer incidence after infertility and in vitro fertilization. Lancet 1995;346(8981):995–1000.CrossRefGoogle Scholar
Dor, J, Lerner-Geva, L, Rabinovici, J, et al. Cancer incidence in a cohort of infertile women who underwent in vitro fertilization. Fertil Steril 2002;77(2):324–27.CrossRefGoogle Scholar
Klip, H, Burger, C W, Van Leeuwen, F E. The Omega Project Group. Risk of hormone-related cancers after ovarian stimulation for in-vitro fertilization in a cohort of 25,152 women. Enschede Netherlands PrintPartners Ipskamp BV 2002;1:55–82.Google Scholar
Källén, B, Finnström, O, Lindam, A, et al. Malignancies among women who gave birth after in vitro fertilization. Hum Reprod 2011;26(1):253–58.CrossRefGoogle ScholarPubMed
Yli-Kuha, A N, Gissler, M, Klemetti, R, Luoto, R, Hemminki, E. Cancer morbidity in a cohort of 9175 Finnish women treated for infertility. Hum Reprod 2012;27(4):1149–55.CrossRefGoogle Scholar
Brinton, L A, Trabert, B, Shalev, V, et al. In vitro fertilization and risk of breast and gynecologic cancers: a retrospective cohort study within the Israeli Maccabi Healthcare Services. Fertil Steril 2013;99(5):1189–96.CrossRefGoogle ScholarPubMed
Van Leeuwen, F E, Klip, H, Mooij, T M, et al. Risk of borderline and invasive ovarian tumours after ovarian stimulation for in vitro fertilization in a large Dutch cohort. Hum Reprod 2011;26(12):3456–65.CrossRefGoogle Scholar
Bjørnholt, S M, Krüger Kjaer, S, Schütt Svane, Tn, et al. Risk for borderline ovarian tumours after exposure to fertility drugs: results of a population-based cohort study. Hum Reprod 2005;30:222–31.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×